Skip to main content
Theraclion SA logo

Theraclion SA — Investor Relations & Filings

Ticker · ALTHE ISIN · FR0010120402 LEI · 9695007X7HA7A1GCYD29 PA Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2017-11-20 Regulatory Filings
Country FR France
Listing PA ALTHE

About Theraclion SA

https://www.theraclion.com/?_ga=2.14878…

Theraclion SA is a medical device company specializing in the development and marketing of non-invasive therapeutic solutions using High-Intensity Focused Ultrasound (HIFU). The company's technology, known as echotherapy, provides a non-surgical alternative for tissue ablation. Its flagship product, SONOVEIN®, is a robotic solution for the non-invasive treatment of varicose veins. The system uses external ultrasound beams to ablate the target vein without incisions, catheters, or sedation, allowing for immediate patient recovery. Theraclion also developed ECHOPULSE®, a system for the treatment of thyroid nodules and breast fibroadenomas. The company's core focus is on providing precise, non-invasive treatments that reduce risks and recovery time compared to traditional surgical procedures.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from THERACLION dated November 20, 2017, announcing the presentation of new clinical data for its Echopulse® system at the Radiological Society of North America (RSNA) meeting. It details study results, ongoing clinical trials, and quotes management. This type of announcement, focusing on clinical data presentation, strategic updates, and general company news outside of mandatory financial filings (like 10-K, ER, or IR), most closely aligns with a general Investor Relations communication. Since it is not a formal financial report (10-K, IR, ER) nor a specific regulatory filing like a Director's Dealing or Capital Change, and it serves to inform investors about scientific progress and upcoming presentations, it fits best under the general 'Regulatory Filings' (RNS) category as a broad corporate announcement, or potentially an Investor Presentation (IP) if it were the slides themselves. Given the format is a press release announcing data presentation rather than the presentation slides or a formal financial report, RNS is the most appropriate fallback for non-standard corporate news releases.
2017-11-20 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 90% confidence The document is a press release from THERACLION announcing that clinical data regarding their Echopulse® device for treating breast fibroadenomas will be presented at the RSNA conference. It details the study results, the ongoing pivotal trial, and includes quotes from investigators and management. This type of announcement, focusing on clinical data presentation and trial updates, is characteristic of general corporate or investor news, but it is not a formal regulatory filing (like 10-K, IR, ER), nor is it a specific report like an Audit Report (AR) or a Management Discussion & Analysis (MDA). Since it is an announcement about company activities, clinical progress, and future data releases, it fits best under the general 'Regulatory Filings' (RNS) category as a broad corporate communication, or potentially an Investor Presentation (IP) if it were the presentation itself, but here it is the *announcement* of the presentation. Given the options, RNS serves as the best general category for non-standard, non-financial regulatory/corporate news releases that don't fit the highly specific categories like DIRS, DIV, or CAP. It is not a Report Publication Announcement (RPA) because it is announcing data presentation, not the publication of a formal financial report.
2017-11-20 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated November 15, 2017, announcing the presentation of preliminary clinical trial results regarding the use of Echotherapy (HIFU) for treating varicose veins. It details the study's feasibility, safety, and patient satisfaction, and includes quotes from the CEO and the lead investigator. This content structure—announcing study findings, often referencing a presentation or webcast replay—is characteristic of an Earnings Release (ER) if it were focused on financial performance, or potentially an Investor Presentation (IP) if it were the slides themselves. However, since this is a formal announcement of clinical/operational progress, and not a comprehensive financial report (10-K, IR) or a transcript (CT), it best fits the category for initial operational/clinical updates. Given the options, it is a release of significant operational news, which often overlaps with ERs, but since it is focused purely on clinical trial results and not quarterly financials, it is most closely aligned with a general announcement of important company information. Since it is a formal announcement of results/progress, and not a full report, it is not 10-K or IR. It is not a management discussion (MDA) or a presentation (IP). It is a news release detailing progress. In the absence of a specific 'Clinical Trial Update' category, this type of announcement, which is a formal release of key operational/scientific progress, is often categorized as an Earnings Release (ER) if it's periodic, or a Regulatory Filing (RNS) if it's purely informational and not financial. Given the context of presenting preliminary results, it functions as a significant operational update. However, looking closely at the definitions, it is a news announcement about study results, not a formal regulatory filing (RNS) or a financial earnings release (ER). Since it is a formal announcement of progress, and not a full report, and doesn't fit other specific categories like M&A or Capital, the most appropriate general category for a significant, non-financial operational update announcement is often RNS, or if it's considered a precursor to financial reporting, ER. Given the structure, it reads like a press release detailing operational milestones. I will classify this as a Regulatory Filing (RNS) as it is a general announcement of material information that doesn't fit the other specific categories like DIV, CAP, or ER (which usually focuses on revenue/profit). It is short and announces information, fitting the spirit of RNS as a general announcement category.
2017-11-15 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated November 15, 2017, announcing preliminary results from a clinical study on Theraclion's echotherapy for treating varicose veins. It details study findings, quotes the CEO, and provides background on the principal investigator and the company. This format—a formal announcement of new data or findings, often released outside of standard quarterly/annual filings—is characteristic of an Earnings Release (ER) if it were financial results, or more generally, a significant corporate update. Since it is presenting clinical trial results and not comprehensive financial performance (like a 10-K or IR), and it is a formal announcement, it aligns best with an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the structure focusing on study outcomes and quotes, it functions as a high-level announcement of operational/clinical progress, similar to how an ER presents key performance indicators. However, since it is not explicitly financial earnings, and it is a press release format, the most fitting category among the options for a significant, non-standard announcement is often ER if it's performance-related, or RNS if it's a general regulatory update. Since it's a presentation of study results, which drives future performance, ER is a strong candidate, but given the context of clinical data presentation, it is often categorized as a general corporate announcement. Since it is a detailed announcement of results, and not just a notice that a report is available (which would be RPA), I will classify it as an Earnings Release (ER) as it communicates key performance/progress metrics, or RNS as a general announcement. Given the focus on clinical trial results, which are often presented alongside or instead of financial results in biotech/medtech, ER is plausible, but RNS is the safest fallback for non-standard announcements. I will lean towards RNS as it is a general press release format announcing study outcomes, not a formal financial report or a specific management/board change.
2017-11-15 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is an announcement from Theraclion stating they will host a conference call and webinar to discuss the preliminary results of a clinical trial concerning echotherapy for varicose veins. It provides the date, time, dial-in numbers, and a link to the live webinar, which will be archived. This structure—announcing an event to discuss results or information, rather than containing the full report or transcript itself—strongly indicates a communication designed to inform investors about an upcoming event. Since it is an announcement about discussing clinical trial results, it is not a full Earnings Release (ER), Interim Report (IR), or Call Transcript (CT). It is an announcement related to company activity and investor communication, but the most fitting category for an announcement about a presentation/call is often related to investor events or general regulatory updates. Given the options, this is an announcement about presenting specific clinical/trial information, which often falls under general investor relations communication. However, since it is specifically announcing a call to discuss results, and not a formal regulatory filing like a 10-K or a formal earnings release, it functions as a general corporate update. If the document were the transcript of the call, it would be 'CT'. Since it is the *invitation* to the call, and it is not a formal financial report, it is best classified as a general announcement. Given the options, and recognizing that it is an announcement about presenting data, it is closest to a general corporate update or a specific type of investor communication. Since there isn't a specific 'Webinar Announcement' code, and it's not a formal financial report, 'RNS' (Regulatory Filings/General Announcements) is a possibility, but 'IP' (Investor Presentation) is often used for materials presented to investors. Since this is an announcement *of* a presentation/call, and not the presentation itself, 'RPA' (Report Publication Announcement) is sometimes used for announcements of corporate events, but 'RNS' is the safest fallback for non-standard announcements. Given the context of discussing trial results, it is a specific corporate update. I will lean towards RNS as the most appropriate general regulatory/corporate announcement category when a more specific event type (like a formal earnings call transcript) is not present.
2017-11-06 English
Information relating to the total number of voting rights and shares making up the capital
Major Shareholding Notification Classification · 99% confidence The document explicitly announces an update to the distribution of the company's share capital following a recent capital increase via a private placement. It details the number of new shares issued, the subscription price, the impact on total shares and voting rights, and compares the current structure to a previous date (May 11, 2017). This content directly relates to changes in the company's capital structure and ownership percentages, which aligns best with the 'Share Issue/Capital Change' definition (SHA). It is not a general earnings release (ER), a full annual report (10-K), or a simple announcement of a report (RPA).
2017-11-03 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.